2020-07-14T07:36:39-05:00 2019-06-30 GRANT THORNTON LLP 75 State Street Boston MA 02109 990 2018-07-01 042104230 Forsyth Dental Infirmary for Children % WANDA CORDOVA FORS 6172625200 245 First Street Cambridge MA 02142 WANDA CORDOVA CFO 6172625200 2020-07-08 true Erin Couture P01390592 6177237900 69.248.129.53 04586620201965000000 2020-07-14 P 8DA45669AA757E6CBAFC89028E986B6FFD72D25A 3426759E5436679D67E81126D5284ACE9FC9833D 2018 2021-01-29 14:40:06Z The Forsyth Institute Wenyuan Shi CEO 245 First Street Cambridge MA 02142 21127778 false X www.forsyth.org X 1910 MA TO IMPROVE ORAL AND OVERALL HEALTH THROUGH COMBINATION OF INNOVATIVE RESEARCH AND COMMUNITY OUTREACH BY ACCELERATING THE DELIVERY OF WELLNESS SOLUTIONS INTO THE REAL WORLD. 19 18 159 103 729897 -618958 11497146 13809241 3620403 4096235 2687455 2082457 387635 1032193 18192639 21020126 1707927 1620446 0 0 12156573 12488907 0 0 263911 18421760 11917454 32286260 26026807 -14093621 -5006681 61681227 52655810 9748235 6277101 51932992 46378709 X The Forsyth Institute was founded to provide free dental care to Boston's poorest children. It was quickly determined that treating the ravages of dental disease (Schedule O) false false 19247626 1620446 4233046 OVER THE PAST 100 YEARS, FORSYTH HAS EVOLVED INTO AN INNOVATIVE CENTER FOR BIOMEDICAL RESEARCH. MANY OF FORSYTH'S SCIENTISTS USE THE MOUTH AS A PORTAL TO LEARN MORE ABOUT THE BODY; AND ARE EXAMINING HOW BONE LOSS OCCURS AND HOW INFLAMMATION CONTRIBUTES TO SYSTEMIC DISEASES SUCH AS DIABETES AND HEART DISEASE. OTHERS ARE INVESTIGATING THE ROLES THAT BACTERIA IN AND ON THE HUMAN BODY (OUR MICROBIOME) PLAY IN HEALTH AND DISEASE - FROM CAVITIES TO PNEUMONIA. THE INSTITUTE'S FOUNDING PUBLIC HEALTH MISSION REMAINS STRONG THROUGH THE FORSYTHKIDS PROGRAM, A NOVEL MOBILE SERVICE DELIVERING DENTAL CARE TO THOUSANDS OF UNDERSERVED CHILDREN ANNUALLY. 19247626 true true false true false false false false false true true true false false true true false true false false true true false false true false false true false true false false false false false false false false false false false false true true true true false false true 41 0 true 159 true true true false false false false false false false false false false false X 19 18 false false false false false false false true true false false true true true true true true true true true true MA X X WANDA CORDOVA 6178928367 245 FIRST STREET Cambridge MA 02142 MR PETER NESSEN Chairman of the Board 4.0 0.0 X X 0 0 0 DR DAVID W ELLIS Vice Chair 1.0 0.0 X X 0 0 0 MR RICHARD ANDERS Director 1.0 0.0 X 0 0 0 MS JANICE BOURQUE Director 1.0 0.0 X 0 0 0 MS PAMELA CARRINGTON SCOTT DIRECTOR (as of 06/2019) 1.0 0.0 X 0 0 0 MS ELYSE D CHERRY Director 1.0 0.0 X 0 0 0 MS CATHERINE D'AMATO Director 1.0 0.0 X 0 0 0 DR BRUCE DONOFF Director 1.0 0.0 X 0 0 0 MR DAI FENG Director 1.0 0.0 X 0 0 0 DR JOHN FICARELLI Director 1.0 0.0 X 0 0 0 MS ROSALEE HERMENS Director 1.0 0.0 X 0 0 0 MS KARLA L JARVIS Director 1.0 0.0 X 0 0 0 MS JANET KELLY Director 1.0 0.0 X 0 0 0 MR STEVEN KESS Director (thru 10/2018) 1.0 0.0 X 0 0 0 MR RAJI KOHLI DIRECTOR (as of 03/2019) 1.0 0.0 X 0 0 0 MR MICHAEL MONOPOLI Director 1.0 0.0 X 0 0 0 MR JOHN M PLUKAS Director 1.0 0.0 X 0 0 0 MR J BRIAN POTTS Director (thru 10/2018) 1.0 0.0 X 0 0 0 MR WALTER M PRESSEY Director 1.0 0.0 X 0 0 0 MS ROBYN REDFIELD Director 1.0 0.0 X 0 0 0 DR ANTHONY R VOLPE Director (thru 10/2018) 1.0 0.0 X 0 0 0 DR WENYUAN SHI Pres, Chief Sc. Off & CEO 45.0 0.0 X X 391857 0 31755 MS WANDA CORDOVA CFO & TREASURER 45.0 0.0 X 211394 0 19636 MS GENEVIEVE HOLMES CHIEF PROJECT OFFICER & SEC 45.0 0.0 X 97352 0 10930 DR THOMAS E VAN DYKE VP CLINICAL & TRANS. RES. 45.0 0.0 X 308887 0 26066 DR PRAMOD M SOPARKAR Senior Scientist 45.0 0.0 X 220521 0 34740 DR FLOYD DEWHIRST Senior Scientist 45.0 0.0 X 217909 0 44251 DR IBRAHIM KANTARCI Associate Scientist 45.0 0.0 X 188684 0 24717 DR MARGARET DUNCAN Senior Scientist 45.0 0.0 X 188071 0 16650 Dr Hatice Hasturk Associate Scientist 45.0 0.0 X 172583 0 23184 1997258 0 231929 28 false true false Aqueduct Technologies Inc 333 Wyman Street Suite 300 WALTHAM MA 02451 IT Managed Services 311163 Foley Hoag LLP 155 Seaport Boulevard BOSTON MA 02210 Legal 255430 Solomon McCown Co Inc 177 Milk Street Suite 610 BOSTON MA 02109 Communications 173349 Wise Construction 21 East Street WINCHESTER MA 01890 Construction 147457 Clappazzola Partners PO Box 419 MASPHEE MA 02649 Event Planning 121000 5 30010 10156020 3623211 13809241 RESEARCH 541700 1569978 1569978 0 0 DENTAL SERVICES 621400 1129339 399442 729897 0 FESC RESEARCH CENTER 541700 1396918 1396918 0 0 4096235 1215749 1215749 0 837171 837171 0 0 0 863708 3000 863708 3000 866708 866708 115017 30010 107652 7365 7365 0 0 0 0 0 0 MISCELLANEOUS INCOME 900099 187657 0 0 187657 187657 21020126 4233046 729897 2247942 1523791 1523791 0 96655 96655 0 1129066 254108 791554 83404 0 8441117 6087616 2321520 31981 667890 467396 191293 9201 1617659 1023438 575141 19080 633175 413012 212328 7835 0 182774 77415 102879 2480 80293 80293 68496 66190 2306 0 159065 159065 692056 240827 442827 8402 18114 18114 0 281708 13604 259012 9092 293010 293010 4807569 4502507 260743 44319 254818 153790 69815 31213 0 86054 20585 60973 4496 10732 10732 0 2810112 2749339 52846 7927 185102 17394 167708 SUPPLIES 1013576 911640 101306 630 LOSS ON ASSETS 327956 327956 0 0 OTHER EXPENSES 646019 300363 341805 3851 26026807 19247626 6515270 263911 914752 537481 305000 305000 0 0 3435250 2400428 0 0 0 0 0 0 0 0 237496 281060 29577265 20106811 12509774 9470454 0 34788407 44278955 4872980 0 0 0 0 0 0 61681227 52655810 2461533 1834699 0 0 652310 292203 0 0 0 0 0 0 0 0 2000000 0 4634392 4150199 9748235 6277101 X 7588886 46371208 43844106 7501 500000 0 51932992 46378709 61681227 52655810 -5006681 -547602 X false true X true true true X 18828815 15255665 16616306 11497146 13809241 76007173 4356952 6921017 2190176 2920350 3366338 19754833 0 0 0 23185767 22176682 18806482 14417496 17175579 95762006 15000 57075 37585 32050 10500 152210 746234 1558289 1536558 3841081 15000 57075 783819 1590339 1547058 3993291 91768715 1167224 996363 661633 1063100 2052920 5941240 0 1167224 996363 661633 1063100 2052920 5941240 0 248556 173513 184461 493402 302674 1402606 24601547 23346558 19652576 15973998 19531173 103105852 0.89004 0.92195 0.05762 0.04310 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 68496 68496 25799246 25867742 1000000 250000 false 1000000 1000000 1000000 1000000 4000000 6000000 13384 12060 68133 68496 162073 250000 250000 250000 250000 1000000 1500000 LOBBYING ACTIVITY EXPENSES INCLUDE A CONTRACT WITH A LOBBYING FIRM FOR ASSISTANCE WITH STATE GRANT LOBBYING. THIS ARRANGEMENT BEGAN IN MAY 2017. ADDITIONALLY, FORSYTH BELONGS TO MEMBERSHIP ORGANIZATIONs WHICH ENGAGE IN LOBBYING ACTIVITIES. A PORTION OF THE DUES PAID ARE SPECIFICALLY IDENTIFIED AS LOBBYING EXPENSES. 44278955 2371539 1341452 8330559 39661387 49276967 4245291 9243303 44278955 50258923 5209122 6191078 49276967 58466801 -1362958 6844920 50258923 61378494 280367 3192060 58466801 1.00000 0.00000 0.00000 false true 0 16774746 9492849 7281897 0 11332190 9741740 1590450 0 1470329 872222 598107 9470454 PRIVATE EQUITY INVESTMENTS 4872980 F 4872980 0 DEFERRED RENT 4150199 4150199 X 20313459 -547602 -547602 20861061 159065 159065 21020126 25867742 25867742 159065 159065 26026807 INTENDED USES OF ENDOWMENT FUNDS SCHEDULE D, PART V, LINE 4 TO SUPPORT THE CHARITABLE MISSION OF THE FORSYTH DENTAL INFIRMARY FOR CHILDREN. ASC 740 FOOTNOTE SCHEDULE D, PART X, LINE 2 The Institute (and Forsyth International) are organizations described in Section 501(c)(3) of the Internal Revenue Code, as amended (the "Code"), and are generally exempt from income taxes pursuant to Section 501(a) of the Code. The Institute to identify uncertain tax positions and has determined that no such positions exist that are material to the financial statements. true Europe (Including Iceland and Greenland) Grantmaking Research 87497 North America Grantmaking Research 9158 96655 96655 Europe (Including Iceland and Greenland) Program Support 67780 check North America Program Support 9158 check Europe (Including Iceland and Greenland) program supp 19718 check 3 false false false false false true SCHEDULE F, PART I, LINE 2 THE INSTITUTE ASSIGNS RESPONSIBILITY FOR MONITORING THE USE OF GRANT FUNDS OUTSIDE OF THE UNITED STATES TO ITS OFFICE OF SPONSORED RESEARCH. THIS OFFICE MONITORS ALL GRANT MAKING ACTIVITY INCLUDING ALL APPLICABLE COMPLIANCE REGULATIONS. MONITORING INCLUDES PERIODIC REVIEWS OF BUDGET TO ACTUAL REPORTS BY BOTH THE OFFICE OF SPONSORED RESEARCH AND THE PRINCIPAL INVESTIGATOR TO ENSURE FUNDS ARE USED ACCORDING TO THE AGREEMENT. EXPENSES ARE ACCOUNTED FOR ON AN ACCRUAL BASIS. schedule F, part I, Line 3, Column(f) the institute uses the accrual method of accounting. MA TASTE & TOAST 145027 30010 115017 107652 0 145027 30010 115017 107652 107652 7365 true Brigham & Women's Hospital 77 Louis Paster Avenue Boston MA 02115 042312909 501(c)(3) 114664 Program Support Boston University 1 Silber Way Boston MA 02215 042103547 501(c)(3) 243608 Program Support Marine Biological Laboratory 7 Mbl Street Woods Hole MA 02543 042104690 501(c)(3) 145899 Program Support Massachusetts General Hospital 210 Longwood Avenue Boston MA 02115 042697983 501(c)(3) 131137 Program Support Massachusetts Institute of Technology 77 Massachusetts Avenue Cambridge MA 02139 042103594 501(c)(3) 123460 Program Support Northwestern University 633 Clark Street Evaston IL 60208 362167817 501(c)(3) 49746 Program Support Stanford University 3160 Porter Drive Palo Alto CA 94304 941156365 501(c)(3) 144025 Program Support Tufts Medical Center 800 Washington Street Boston MA 02111 043400617 501(c)(3) 254067 Program Support The University of Florida Board of Trustees PO Box 113001 Gainesville FL 32611 596002052 GOV'T 29679 Program Support University of Washington 4300 Roosevelt Way NE Seattle WA 98195 916001537 GOV'T 282897 Program Support Vanderbilt University Medical Center 23rd Ave S at Pierce Nashville TN 37232 620476822 501(c)(3) 5405 Program Support 11 ORGANIZATION'S PROCEDURES FOR MONITORING THE USE OF GRANTS IN THE U.S. SCHEDULE I, PART I, LINE 2 THE INSTITUTE ASSIGNS RESPONSIBILITY FOR MONITORING THE USE OF GRANT FUNDS TO ITS OFFICE OF SPONSORED RESEARCH. THIS OFFICE MONITORS ALL GRANT MAKING ACTIVITY INCLUDING ALL APPLICABLE COMPLIANCE REGULATIONS. MONITORING INCLUDES PERIODIC REVIEWS OF BUDGET TO ACTUAL REPORTS BY BOTH THE OFFICE OF SPONSORED RESEARCH AND THE PRINCIPAL INVESTIGATOR TO ENSURE FUNDS ARE USED ACCORDING TO THE AGREEMENT. EXPENSES ARE ACCOUNTED FOR ON AN ACCRUAL BASIS. X X X X false false false false false false false false false DR WENYUAN SHI Pres, Chief Sc. Off & CEO 388503 0 0 0 3354 0 24788 0 6967 0 423612 0 0 0 MS WANDA CORDOVA CFO & TREASURER 209917 0 0 0 1477 0 19636 0 0 0 231030 0 0 0 DR THOMAS E VAN DYKE VP CLINICAL & TRANS. RES. 302576 0 0 0 6311 0 24920 0 1146 0 334953 0 0 0 DR PRAMOD M SOPARKAR Senior Scientist 210930 0 0 0 9591 0 19669 0 15071 0 255261 0 0 0 DR FLOYD DEWHIRST Senior Scientist 212364 0 0 0 5545 0 20025 0 24226 0 262160 0 0 0 DR IBRAHIM KANTARCI Associate Scientist 187608 0 0 0 1076 0 17173 0 7544 0 213401 0 0 0 DR MARGARET DUNCAN Senior Scientist 183744 0 0 0 4327 0 16650 0 0 0 204721 0 0 0 Dr Hatice Hasturk Associate Scientist 171839 0 0 0 744 0 15640 0 7544 0 195767 0 0 0 MISSION STATEMENT (CONTINUED) FORM 990, PART III, LINE 1 was simply impossible given the limitations in knowledge of their causes and best means of prevention - thus began an exciting journey of scientific discovery. In the decades following, our research helped to transform the way the world understands oral health. Forsyth scientists have demonstrated distinct connections between oral diseases and health challenges like heart disease, diabetes, and even certain cancers, and are tackling other global infectious diseases like tuberculosis and HIV/AIDS. We have assembled a world class, multidisciplinary scientific team capable of system-wide approaches to biomedical innovation with the potential for profound impact. Because the Forsyth team combines the best knowledge of oral and systemic diseases with a relentless drive to ask - and answer - new questions, we have made many paradigm setting scientific and medical advances. As an independent research institute, we have the freedom to follow our science wherever it leads, and to collaborate with a broad spectrum of stakeholders - other research organizations, industry, practicing professionals, public leaders, and patients - to meet our shared goals. In the years ahead, the Forsyth will continue to leverage its unique knowledge of oral and associated systemic diseases to elucidate new biomedical insights, and to find the best ways - unfettered by convention-to help billions live healthier lives. FORM 990 REVIEW PROCESS FORM 990, PART VI, SECTION B, LINE 11B THE RETURN WAS PREPARED BY TAX ADVISORS FROM A NATIONAL ACCOUNTING FIRM WITH INFORMATION PROVIDED BY MANAGEMENT. THE DRAFT FORM 990 IS REVIEWED BY THE CEO, CFO, AND THE AUDIT, risk & Compliance COMMITTEE OF THE BOARD OF DIRECTORS. IT IS THEN DISTRIBUTED TO EACH MEMBER OF THE BOARD OF DIRECTORS FOR REVIEW BEFORE FILING. CONFLICT OF INTEREST POLICY MONITORING & ENFORCEMENT FORM 990, PART VI, SECTION B, LINE 12C FORSYTH'S CONFLICT OF INTEREST POLICY APPLIES TO FORSYTH'S BOARD MEMBERS, OFFICERS, ADMINISTRATORS, AND RESEARCH EMPLOYEES AND WAS ESTABLISHED TO PROTECT THE INTEREST OF THE INSTITUTE - THE DESIGN, CONDUCT, OR REPORTING OF OPERATIONS OR RESEARCH. CONSISTENT WITH THE POLICY, OFFICERS, ADMINISTRATORS, RESEARCH STAFF EMPLOYEES AND BOARD MEMBERS ARE REQUIRED TO COMPLETE AN ANNUAL CONFLICT OF INTEREST DISCLOSURE FORM. TO ACCOMPLISH THIS OBJECTIVE, THIS POLICY ESTABLISHES A DISCLOSURE SYSTEM WHEREBY POTENTIAL CONFLICT SITUATIONS WILL BE IDENTIFIED, REVIEWED AND ADDRESSED. FORSYTH OFFICERS, ADMINISTRATORS, AND RESEARCH EMPLOYEES - FORSYTH'S CHIEF GENERAL COUNSEL IS THE INSTITUTIONAL OFFICIAL WHO IS RESPONSIBLE FOR DISSEMINATING THE CONFLICT OF INTEREST POLICY AND COLLECTING SIGNED DISCLOSURE STATEMENTS WHEN THE EMPLOYEES ARE FIRST HIRED AND ANNUALLY THEREAFTER. THE RESOLUTION OF ANY CONFLICT OR PERCEIVED CONFLICT IS IDENTIFIED BY THE INSTITUTIONAL OFFICIAL, IN CONSULTATION WITH FORSYTH'S CONFLICT OF INTEREST COMMITTEE. FORSYTH BOARD MEMBERS - THE SECRETARY OF THE BOARD IS RESPONSIBLE FOR DISSEMINATING THE CONFLICT OF INTEREST POLICY AND COLLECTING SIGNED DISCLOSURE STATEMENTS FROM BOARD MEMBERS AT THE TIME THEY ARE APPOINTED AND ANNUALLY THEREAFTER. THE RESOLUTION OF ANY CONFLICT OR PERCEIVED CONFLICT IS IDENTIFIED BY THE SECRETARY IN CONSULTATION WITH THE CHAIRMAN OF FORSYTH'S BOARD OF DIRECTORS. AS A VOTING BOARD MEMBER, THE CEO DOES NOT VOTE ON AND IS RECUSED WHEN A CONFLICT OF INTEREST ARISES. PROCESS FOR DETERMINING COMPENSATION FORM 990, PART VI, SECTION B, LINES 15A AND 15B CEO COMPENSATION IS REVIEWED AND APPROVED ANNUALLY BY THE INDEPENDENT BOARD OF DIRECTORS. COMPARABLE COMPENSATION DATA AND FORM 990 DATA FROM OTHER ORGANIZATIONS ARE UTILIZED FOR THE REVIEW OF CEO COMPENSATION. THE CEO REVIEWS AND APPROVES COMPENSATION FOR THE EXECUTIVE MANAGEMENT, USING MARKET SURVEYS AND FORM 990 DATA FOR OTHER SIMILAR ORGANIZATIONS. THESE DECISIONS ARE REVIEWED BY THE BOARD OF DIRECTORS. ANNUALLY, FORSYTH PARTICIPATES IN A COMPENSATION SURVEY THAT INCLUDES COMPARATIVE DATA OF SIMILAR ORGANIZATIONS. THESE ANALYSES ARE UTILIZED IN THE REVIEW OF THE CEO AND EXECUTIVE MANAGEMENT'S COMPENSATION. BOTH THE DELIBERATION AND DECISION PROCESS FOR DETERMINING COMPENSATION OF THE CEO AND EXECUTIVE MANAGEMENT IS CONTEMPORANEOUSLY DOCUMENTED. HOW DOCUMENTS ARE MADE AVAILABLE TO THE PUBLIC THE FORSYTH INSTITUTE MAKES ITS GOVERNING DOCUMENTS, WRITTEN POLICIES AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC. THESE ITEMS ARE AVAILABLE UPON REQUEST. Forsyth Innovation LLC 245 First Street Cambridge MA 02142 Tech Dev DE 0 0 Forsyth Forsyth International Inc 245 FIRST STREET CAMBRIDGE MA 02142 043443294 DENTAL CARE MA 501(C)(3) 09 FORSYTH true Beneficial Interest in Trust Trust MA Forsyth trust 2582925 1.00000 true false false false false false false false false false false false false false false false false false false true Beneficial Interest in trust S 44278955 cash/stock inv.